Bayer Raises €3 Billion to Enhance Financial Flexibility and Capital Position
Bayer has taken a significant step to reinforce its financial position after securing €3.0 billion in equity capital through a strategic investment agreement with global asset management firm Apollo. The transaction is designed to strengthen Bayer’s capital structure, improve financial flexibility, and support the company’s long-term strategic priorities while allowing it to maintain full operational control of one of its core pharmaceutical businesses.
Under the agreement announced on Friday, Apollo-managed funds and affiliated investment entities will acquire a minority, non-controlling stake in a newly established company that will hold Bayer’s long-acting reversible contraceptives (LARC) business. Bayer will continue to own the majority stake in the newly formed entity and will retain complete responsibility for managing the operations, strategy, and future direction of the business.
The investment does not represent a change in Bayer’s approach to its LARC portfolio. The company confirmed that there will be no adjustments to the business strategy, product activities, or operational structure as a result of the transaction. The LARC business will remain an important component of Bayer’s Pharmaceuticals Division and will continue to be treated as a core area of the company’s healthcare operations.
Despite Apollo’s minority investment, Bayer will continue to fully consolidate the entity within the Bayer Group’s Consolidated Financial Statements. This ensures that the company maintains financial reporting continuity while gaining access to additional capital resources.
Bayer Chief Financial Officer Dr. Judith Hartmann described the agreement as a strategic financing measure that provides the company with greater financial strength and flexibility.
“This transaction represents a strategic financing solution that strengthens our capital structure while preserving full operational control over this core pharmaceuticals business,” said Dr. Hartmann. “It enhances our financial flexibility as we manage increased liquidity requirements this year related to bond maturities and litigation procedures, while continuing to execute our long-term priorities.”
The additional capital comes at an important time for Bayer as the company continues to manage financial commitments, including upcoming debt obligations and ongoing litigation-related expenses. By bringing in external equity capital while retaining control of its pharmaceutical operations, Bayer aims to improve its balance sheet position without compromising its ability to execute its business strategy.
The transaction reflects Bayer’s broader efforts to optimize its financial structure and create greater resilience in a challenging operating environment. The company has been focused on strengthening cash flow, managing liabilities, and maintaining investment capacity across its healthcare and agricultural businesses.
Apollo Partner Jamshid Ehsani highlighted the strategic importance of the investment and emphasized the role of Apollo’s High Grade Capital Solutions platform in supporting established global companies seeking flexible financing options.
“We are proud to invest in the LARC business of Bayer, a global life sciences leader and an iconic German company,” said Ehsani. “This transaction reflects the core purpose of Apollo’s High Grade Capital Solutions platform – providing large, flexible, and bespoke capital to blue-chip corporations — enabling Bayer to strengthen its balance sheet while retaining full operational control over a core business.”
The agreement demonstrates a growing trend among major corporations to explore alternative financing solutions that provide access to capital while allowing companies to preserve ownership and strategic decision-making authority. Through this partnership, Bayer gains a financial partner with experience in large-scale investments while maintaining leadership over its pharmaceutical activities.
Bayer’s LARC business is focused on long-acting reversible contraceptive solutions, which play an important role in women’s healthcare by providing effective and convenient options for pregnancy prevention. The company has established a strong presence in this field through its pharmaceutical expertise and global healthcare capabilities.
The newly established structure will allow Bayer to unlock additional financial resources from the value of the LARC business while continuing to drive innovation, commercial activities, and patient access initiatives. The company emphasized that customers, healthcare professionals, and partners should expect business operations to continue without disruption following completion of the transaction.
The closing of the agreement is expected during the third quarter of 2026, pending approval from relevant antitrust authorities and the completion of customary closing conditions. Until the transaction is finalized, Bayer and Apollo will continue working through the necessary regulatory and administrative processes.
Bayer received financial advice from BofA Securities and Deutsche Bank, which supported the company throughout the transaction process. Legal guidance was provided by Linklaters LLP. Apollo Funds were advised by Latham & Watkins LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP, and NautaDutilh N.V.
With this €3 billion equity investment, Bayer is positioning itself to enhance financial stability while continuing to focus on its core life sciences businesses. The agreement provides the company with additional resources to navigate near-term financial challenges while preserving the operational independence and long-term growth potential of its LARC portfolio.
Source Link:https://www.bayer.com/
